PASADENA, Calif. --(BUSINESS WIRE)--Apr. 26, 2023-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the appointment of Nancy Valente , M.D., to Executive Vice
MONROVIA, Calif. , July 15, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced the appointment of Kurt Gustafson
MONROVIA, Calif. , April 17, 2017 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of inflammation and cancer, today announced that Kevin Gorman , Ph.D., chief executive officer of Neurocrine
MONROVIA, Calif. --(BUSINESS WIRE)--May 23, 2019-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced the appointment of Jeremy Grunstein
Xencor Appoints Jeffrey V. Ravetch of The Rockefeller University to its Scientific Advisory Board Monrovia, CAJune 29, 2009 Xencor, Inc., a company using Fc engineering for the discovery and development of next-generation antibodies, today announced the addition of Jeffrey Ravetch,
Xencor Appoints Industry Veteran David R. King as Chairman of its Board of Directors Monrovia, CA — March 19, 2008 — Xencor, Inc., a company developing protein and antibody therapeutics, today announced that it appointed David R. King as Chairman of its Board of Directors. To Xencor, Mr.
Xencor Appoints Former ZymoGenetics CEO, Bruce Carter, to Chairman of the Board Monrovia, CADecember 7, 2009 Xencor, Inc., a company using Fc engineering for the discovery and development of next-generation antibodies, announced today the appointment of Bruce Carter, Ph.D.
MONROVIA, Calif. , Nov. 8, 2018 /PRNewswire/ -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced the appointment of Ellen G.
Xencor Appoints Edgardo Baracchini, Ph.D., to Chief Business Officer Monrovia, Calif. February 9, 2010 Xencor, Inc., a company using Fc engineering for the discovery and development of next-generation antibodies, announced today the appointment of Edgardo Baracchini, Ph.D., to chief
MONROVIA, Calif. , Sept. 2, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced the appointment of Debra Zack ,